ATOS - Atossa Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
15,083
15,083
9,210
6,608
6,645
Selling general and administrative
12,608
12,608
11,311
7,999
10,620
Total operating expenses
27,691
27,691
20,521
14,607
17,265
Operating income or loss
-27,691
-27,691
-20,521
-14,607
-17,265
Total other income/expenses net
-146
-146
-85
-3,221
25.648
Income before tax
-26,960
-26,960
-20,606
-17,828
-17,240
Income tax expense
0
0
0
0
0
Income from continuing operations
-26,960
-26,960
-20,606
-17,828
-17,240
Net income
-26,960
-26,960
-20,606
-17,828
-17,240
Net income available to common shareholders
-26,960
-26,960
-20,606
-22,331
-17,240
Basic EPS
-
-0.21
-0.18
-1.97
-2.03
Diluted EPS
-
-0.21
-0.18
-1.97
-2.03
Basic average shares
-
126,624
116,950
11,309
8,497
Diluted average shares
-
126,624
116,950
11,309
8,497
EBITDA
-
-27,691
-20,498
-14,561
-17,213